{"id":"thvd-201","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"THVD-201 is an immunotherapeutic vaccine that targets HPV antigens to activate the patient's immune system against HPV-infected cells. The vaccine is intended to generate cellular and humoral immune responses that can recognize and eliminate HPV-positive cancer cells, particularly in patients with established HPV-related malignancies.","oneSentence":"THVD-201 is a therapeutic vaccine designed to stimulate immune responses against human papillomavirus (HPV) for the treatment of HPV-related cancers.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:54:05.595Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HPV-positive cervical cancer"},{"name":"HPV-positive head and neck cancer"}]},"trialDetails":[{"nctId":"NCT02485067","phase":"PHASE3","title":"Clinical Study to Assess the Efficacy and Safety of THVD-201 in Patients With OAB","status":"COMPLETED","sponsor":"SK Chemicals Co., Ltd.","startDate":"2015-01","conditions":"Overactive Bladder","enrollment":384},{"nctId":"NCT01036035","phase":"PHASE1","title":"Effects of Novel Combinations of Tolterodine/Pilocarpine on Pharmacokinetics (PK) and Pharmacodynamics (PD) of Tolterodine in Healthy Subjects","status":"COMPLETED","sponsor":"TheraVida, Inc.","startDate":"2009-09","conditions":"Incontinence","enrollment":18}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"THVD-201","genericName":"THVD-201","companyName":"SK Chemicals Co., Ltd.","companyId":"sk-chemicals-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"THVD-201 is a therapeutic vaccine designed to stimulate immune responses against human papillomavirus (HPV) for the treatment of HPV-related cancers. Used for HPV-positive cervical cancer, HPV-positive head and neck cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}